Shares of Moderna Inc. MRNA, +5.21% gained 0.4% in trading on Monday after the biotechnology company said it plans to produce 100 million doses of its COVID-19 vaccine in the first quarter for the U.S. market. That is the equivalent of 50 million vaccinations as the Moderna vaccine requires two doses. Moderna said it has supplied 18 million doses of the vaccine in the U.S. so far, which is enough to vaccinate 9 million people, in the weeks since the vaccine received emergency use authorization from the Food and Drug Administration on Dec. 18. The U.S. government has agreed to purchase 200 million doses of Moderna’s coronavirus vaccine. Moderna’s vaccine is one of two to receive an EUA in the U.S. so far during the pandemic. Globally, Moderna plans to deliver an estimated 500 to 600 million doses in 2021. Moderna’s stock is up 453.0% over the last year, while the S&P 500 [s; spx] has gained 16.2%.